Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Status:
Suspended
Trial end date:
2023-10-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dexamethasone, elotuzumab, pomalidomide work in treating
patients with multiple myeloma that has not responded to previous treatment. Drugs used in
chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Immunotherapy with monoclonal antibodies, such as elotuzumab, may help the body?s
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Pomalidomide may stop the growth of multiple myeloma by blocking the growth of
new blood vessels necessary for tumor growth. Giving dexamethasone, elotuzumab, pomalidomide
may work better in treating patients with multiple myeloma.